Tuberous sclerosis complexes (TSCs) normally inhibit Rheb-directed mTOR activation (54, 56), and mutations in TSC proteins (TSC1-hamartin, TSC2-tuberin) constitutively activate Rheb-mTOR-pS6K and increase cell size (54, 56). Here, RHEB is linked to tuberous sclerosis.